[go: up one dir, main page]

EP3500267A4 - Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs - Google Patents

Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs Download PDF

Info

Publication number
EP3500267A4
EP3500267A4 EP17844270.3A EP17844270A EP3500267A4 EP 3500267 A4 EP3500267 A4 EP 3500267A4 EP 17844270 A EP17844270 A EP 17844270A EP 3500267 A4 EP3500267 A4 EP 3500267A4
Authority
EP
European Patent Office
Prior art keywords
treatment
methods
neurodegenerative disorders
nicotinamide riboside
pterostilbene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17844270.3A
Other languages
German (de)
English (en)
Other versions
EP3500267A1 (fr
Inventor
Eric Alexander Marcotulli
Daniel Antonio Alminana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elysium Health Inc
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of EP3500267A1 publication Critical patent/EP3500267A1/fr
Publication of EP3500267A4 publication Critical patent/EP3500267A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP17844270.3A 2016-08-22 2017-08-22 Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs Pending EP3500267A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378053P 2016-08-22 2016-08-22
PCT/US2017/047979 WO2018039207A1 (fr) 2016-08-22 2017-08-22 Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs

Publications (2)

Publication Number Publication Date
EP3500267A1 EP3500267A1 (fr) 2019-06-26
EP3500267A4 true EP3500267A4 (fr) 2020-03-18

Family

ID=61246253

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17844270.3A Pending EP3500267A4 (fr) 2016-08-22 2017-08-22 Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs

Country Status (12)

Country Link
US (2) US11260069B2 (fr)
EP (1) EP3500267A4 (fr)
JP (1) JP7132907B2 (fr)
KR (1) KR20190046895A (fr)
CN (2) CN115645432A (fr)
AU (1) AU2017316614B2 (fr)
BR (1) BR112019003579A2 (fr)
CA (1) CA3034673A1 (fr)
MX (1) MX2019002211A (fr)
RU (1) RU2019108100A (fr)
WO (1) WO2018039207A1 (fr)
ZA (1) ZA201901536B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039207A1 (fr) 2016-08-22 2018-03-01 Elysium Health, Inc. Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
EP3642214A2 (fr) 2017-06-19 2020-04-29 Gangadhara Ganapati Dérivés de nicotinamide riboside et leurs utilisations
CA3108015A1 (fr) 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions et procedes de prevention et d'inversion des aspects du vieillissement
EP3866811A4 (fr) * 2018-10-19 2022-11-02 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 en combinaison avec nad+ ou un précurseur de nad+
WO2020102326A1 (fr) * 2018-11-13 2020-05-22 Elysium Health, Inc Procédés de détermination et d'augmentation de niveaux de nad
WO2020131578A2 (fr) 2018-12-17 2020-06-25 Mitopower Llc Composés nicotinyl riboside et leurs utilisations
US12350283B2 (en) 2019-02-26 2025-07-08 Universitat De Valencia-Estudi General Methods and compositions for treating motor neuron diseases
CN110812365A (zh) * 2019-11-07 2020-02-21 明特奇点医疗科技（北京）有限公司 一种组合物及其制备方法与制剂
CN111838669B (zh) * 2020-08-07 2022-11-29 四川大学华西医院 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途
EP4079311B1 (fr) 2021-04-20 2025-10-01 Nuvamid SA Nmn et dérivés pour leur utilisation dans le traitement de la dépression et/ou de l'anxiété chez des patients ayant une forme de la maladie de parkinson
WO2022269064A1 (fr) * 2021-06-24 2022-12-29 Vestlandets Innovasjonsselskap As (Vis) Traitement d'augmentation de nad pour la maladie de parkinson
PL4284387T3 (pl) * 2021-06-24 2024-11-25 Vestlandets Innovasjonsselskap As (Vis) Terapia podnosząca poziom NAD w chorobie Parkinsona
WO2023076804A1 (fr) * 2021-10-27 2023-05-04 Elysium Health Inc. Méthodes de traitement de syndromes de la ménopause
CN116807985A (zh) * 2023-06-20 2023-09-29 风火轮(上海)生物科技有限公司 一种烟酰胺核糖组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032870A2 (fr) * 2007-09-07 2009-03-12 The United States Of America, As Represented By The Secretary Of Agriculture Procédé pour traiter le stress oxydatif et améliorer la mémoire de travail par administration de ptérostilbène
EP2574339A1 (fr) * 2011-09-27 2013-04-03 Johannes Huber Préparation pharmaceutique pour le traitement de maladies conditionnées par NADH
WO2016149277A1 (fr) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Compositions nutritionnelles pour améliorer la production d'énergie mitochondriale

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663226T3 (es) 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
CA2610854A1 (fr) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside et analogues
WO2009082459A2 (fr) * 2007-12-24 2009-07-02 Natrol, Inc. Composition anti-vieillissement contenant du resvératrol et méthode d'administration
WO2010095926A1 (fr) * 2009-02-20 2010-08-26 N.V. Nutricia Utilisation du révératrol pour préserver le fonctionnement cognitif
EP2445488B1 (fr) 2009-06-22 2020-03-18 Indus Biotech Private Limited Procédé pour obtenir du ptérostilbène purifié et méthodes d'utilisation
CN102762573B (zh) 2009-07-24 2015-09-16 阿马曾提斯公司 用于在神经退行性障碍中保护脑部健康的化合物、组合物和方法
US9439875B2 (en) 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
US20130149277A1 (en) 2011-12-13 2013-06-13 Cliffstar Llc Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
KR20210107895A (ko) * 2013-10-30 2021-09-01 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
MX2016015997A (es) 2014-06-02 2017-04-05 Glaxosmithkline Intellectual Property (No 2) Ltd Preparacion y uso de beta-d-nicotinamida ribosido cristalina.
WO2016122832A1 (fr) * 2015-01-30 2016-08-04 Natural Formulations Compositions, méthodes thérapeutiques et prophylactiques pour le traitement de maladies neurodégénératives et de lésions cérébrales
WO2018039207A1 (fr) 2016-08-22 2018-03-01 Elysium Health, Inc. Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032870A2 (fr) * 2007-09-07 2009-03-12 The United States Of America, As Represented By The Secretary Of Agriculture Procédé pour traiter le stress oxydatif et améliorer la mémoire de travail par administration de ptérostilbène
EP2574339A1 (fr) * 2011-09-27 2013-04-03 Johannes Huber Préparation pharmaceutique pour le traitement de maladies conditionnées par NADH
WO2016149277A1 (fr) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Compositions nutritionnelles pour améliorer la production d'énergie mitochondriale

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANROOPB NAIR ET AL: "A simple practice guide for dose conversion between animals and human", JOURNAL OF BASIC AND CLINICAL PHARMACY, vol. 7, no. 2, 1 May 2016 (2016-05-01), India, pages 27, XP055407475, ISSN: 0976-0105, DOI: 10.4103/0976-0105.177703 *
GONG BING ET AL: "Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-[gamma] coactivator 1[alpha] regulated [beta]-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 34, no. 6, 9 January 2013 (2013-01-09), pages 1581 - 1588, XP028997200, ISSN: 0197-4580, DOI: 10.1016/J.NEUROBIOLAGING.2012.12.005 *
JAEWON CHANG ET AL: "Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease", NEUROBIOLOGY OF AGING, vol. 33, no. 9, 1 September 2012 (2012-09-01), pages 2062 - 2071, XP55154028, ISSN: 0197-4580, DOI: 10.1016/j.neurobiolaging.2011.08.015 *
JOS� DE LA RUBIA ET AL: "Efficacy and Tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo controlled human pilot study", AMYOTROPHIC LATERAL SCLEROIS AND FRONTOTEMPORAL DEGENERATION, 22 January 2019 (2019-01-22), pages 1 - 8 *
OBRADOR ELENA ET AL: "Nicotinamide Riboside and Pterostilbene Cooperatively Delay Motor Neuron Failure in ALS SOD1G93A Mice", MOLECULAR NEUROBIOLOGY, vol. 58, no. 4, 10 November 2020 (2020-11-10), pages 1345 - 1371, XP037389122, ISSN: 0893-7648, DOI: 10.1007/S12035-020-02188-7 *
See also references of WO2018039207A1 *

Also Published As

Publication number Publication date
JP2019524856A (ja) 2019-09-05
US11260069B2 (en) 2022-03-01
US11998561B2 (en) 2024-06-04
AU2017316614A1 (en) 2019-03-21
KR20190046895A (ko) 2019-05-07
US20220143055A1 (en) 2022-05-12
RU2019108100A (ru) 2020-09-22
CN115645432A (zh) 2023-01-31
JP7132907B2 (ja) 2022-09-07
RU2019108100A3 (fr) 2020-11-27
CN109982706A (zh) 2019-07-05
CA3034673A1 (fr) 2018-03-01
EP3500267A1 (fr) 2019-06-26
BR112019003579A2 (pt) 2019-05-21
MX2019002211A (es) 2019-10-30
US20190201426A1 (en) 2019-07-04
WO2018039207A1 (fr) 2018-03-01
ZA201901536B (en) 2024-06-26
AU2017316614B2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3307754A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles de la peau
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3433266A4 (fr) Méthodes de traitement de troubles mitochondriaux
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3368088C0 (fr) Compositions et méthodes pour le traitement de troubles du peroxisome et de leucodystrophies
EP3445451A4 (fr) Compositions et méthodes pour le traitement de troubles lysosomaux et de troubles caractérisés par un dysfonctionnement lysosomal
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA47212A (fr) Méthodes de traitement de troubles neurologiques
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3621434A4 (fr) Méthodes de traitement de troubles neuropsychiatriques
EP3313417A4 (fr) Méthodes de traitement de troubles auto-immuns et allo-immuns
EP3334710A4 (fr) Compositions et méthodes de traitement et de prévention de troubles neurodégénératifs
EP3377105A4 (fr) Compositions pour le traitement de troubles de la calcification ectopique, et méthodes les utilisant
EP3902536A4 (fr) Compositions et méthodes de traitement de troubles neurodégénératifs
EP3442554A4 (fr) Compositions et méthodes pour le traitement de troubles associés à la néovascularisation
MA42985A (fr) Traitement de troubles liés à l'acide biliaire
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190318

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200213

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/45 20060101ALI20200207BHEP

Ipc: A61K 31/704 20060101AFI20200207BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220830

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN